Drug intelligence / Profile preview

SEL-201

Development stage: Preclinical
Lead developer: Selecta Biosciences
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Oral

Overview

SEL-201 is a drug candidate developed by Selecta Biosciences, utilizing its proprietary Synthetic Vaccine Particle (SVP) platform. It is designed to induce immune tolerance to therapeutic proteins, specifically aiming to prevent the formation of anti-drug antibodies against Factor VIII, which is used in the treatment of hemophilia A.

Targets

MKNK2 (MAP kinase-interacting serine/threonine-protein kinase 2)MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on SEL-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEL-201.

Explore the full profile